BindingDB logo
myBDB logout

123 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
27997164 18 Synthesis of Novel c(AmpRGD)-Sunitinib Dual Conjugates as Molecular Tools Targeting theaEBI Universit£ degli Studi di Parma
27774126 95 ExploringEBI University of California-San Francisco
26753814 7 Cyclic RGD peptidomimetics containing 4- and 5-amino-cyclopropane pipecolic acid (CPA) templates as dualaV▀3 anda5▀1 integrin ligands.EBI University of Florence
24949551 22 Rational improvement of the affinity and selectivity of integrin binding of grafted lasso peptides.EBI Philipps-Universit£t Marburg
24973662 8 Targeting integrinsav▀3 anda5▀1 with new▀-lactam derivatives.EBI University of Bologna
24654918 19 Pharmacophoric modifications lead to superpotentav▀3 integrin ligands with suppresseda5▀1 activity.EBI Technische Universit£t M£nchen
24412498 15 Synthesis and assay of retro-a4▀1 integrin-targeting motifs.EBI University of Bologna
24095096 3 Synthesis and in vitro evaluation of a novel radioligand forav▀3 integrin receptor imaging: [18F]FPPA-c(RGDfK).EBI University Hospital of Geneva
23811088 26 Modulation ofav▀3- anda5▀1-integrin-mediated adhesion by dehydro-▀-amino acids containing peptidomimetics.EBI University of Bologna
23562062 4 Arylsulfonamide pyrimidines as VLA-4 antagonists.EBI Elan Pharmaceuticals, Inc.
23376251 32 Towards dual antithrombotic compounds - balancing thrombin inhibitory and fibrinogen GPIIb/IIIa binding inhibitory activities of 2,3-dihydro-1,4-benzodioxine derivatives through regio- and stereoisomerism.EBI University of Ljubljana
23362923 59 Biselectivity of isoDGR peptides for fibronectin binding integrin subtypesa5ß1 andavß6: conformational control through flanking amino acids.EBI Technische Universit£t M£nchen
20088512 4 One step radiosynthesis of 6-[(18)F]fluoronicotinic acid 2,3,5,6-tetrafluorophenyl ester ([(18)F]F-Py-TFP): a new prosthetic group for efficient labeling of biomolecules with fluorine-18.EBI University of Troms£
19959360 50 SAR of N-phenyl piperidine based oral integrin alpha5beta1 antagonists.EBI Jerini AG
19910191 46 Discovery of orally available integrin alpha5beta1 antagonists.EBI Jerini AG
21601452 2 Tetrazine-trans-cyclooctene ligation for the rapid construction of integrinavß3 targeted PET tracer based on a cyclic RGD peptide.EBI University of Delaware
21349709 6 Exploring new near-infrared fluorescent disulfide-based cyclic RGD peptide analogs for potential integrin-targeted optical imaging.EBI Washington University School of Medicine
20888763 8 Synthesis and evaluation of bivalent, peptidomimetic antagonists of theavß3 integrins.EBI The Methodist Hospital Research Institute
17289386 10 Inhibition of cancer cell adhesion by heterochiral Pro-containing RGD mimetics.EBI Universit£ degli Studi di Bologna
16982193 26 Discovery of small molecule inhibitors of integrin alphavbeta3 through structure-based virtual screening.EBI Chinese Academy of Medical Sciences and Peking Union Medical College
16854058 8 Discovery of small molecule integrin alphavbeta3 antagonists as novel anticancer agents.EBI University of Southern California
16722662 2 Novel and selective alpha(v)beta3 receptor peptide antagonist: design, synthesis, and biological behavior.EBI University of Naples Federico II
16570923 8 Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors.EBI Washington University
15715477 3 Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery.EBI University of Southern California
15369386 11 Nonpeptide alphavbeta3 antagonists. Part 11: discovery and preclinical evaluation of potent alphavbeta3 antagonists for the prevention and treatment of osteoporosis.EBI Merck Research Laboratories
15863341 33 Non-peptidic alpha(v)beta3 antagonists containing indol-1-yl propionic acids.EBI Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
15357963 16 Nonpeptide alpha V beta 3 antagonists. Part 9: Improved pharmacokinetic profile through the use of an aliphatic, des-amide backbone.EBI Merck Research Laboratories
14521404 10 Docking studies on alphavbeta3 integrin ligands: pharmacophore refinement and implications for drug design.EBI Technische Universit£t M£nchen
11020288 13 Nonpeptide alpha(v)beta(3) antagonists. 1. Transformation of a potent, integrin-selective alpha(IIb)beta(3) antagonist into a potent alpha(v)beta(3) antagonist.EBI Merck Research Laboratories
8893849 10 Synthesis and solution conformation of cyclo[RGDRGD]: a cyclic peptide with selectivity for the alpha V beta 3 receptor.EBI Texas A& M University
7650686 3 Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist.EBI Merck Research Laboratories
15013021 10 Non-peptide alpha v beta 3 antagonists. Part 7: 3-Substituted tetrahydro-naphthyridine derivatives.EBI Merck Research Laboratories
12643914 40 Biphenyls as potent vitronectin receptor antagonists. Part 2: biphenylalanine ureas.EBI Bayer AG
14643310 6 Non-peptide alpha(v)beta(3) antagonists: identification of potent, chain-shortened RGD mimetics that incorporate a central pyrrolidinone constraint.EBI Merck Research Laboratories
12419389 13 Non-peptide alpha(v)beta(3) antagonists. Part 5: identification of potent RGD mimetics incorporating 2-aryl beta-amino acids as aspartic acid replacements.EBI Merck Research Laboratories
11755355 32 Biphenyls as potent vitronectin receptor antagonists.EBI Bayer AG
12161158 11 Non-peptide alpha(v)beta(3) antagonists. Part 4: potent and orally bioavailable chain-shortened RGD mimetics.EBI Merck Research Laboratories
11992781 31 Synthesis of highly potent and selective hetaryl ureas as integrin alpha(V)beta3-receptor antagonists.EBI BASF AG
11738567 16 Non-peptide alpha(v)beta(3) antagonists. Part 3: identification of potent RGD mimetics incorporating novel beta-amino acids as aspartic acid replacements.EBI Merck Research Laboratories
11738566 20 Nonpeptide alpha(v)beta(3) antagonists. Part 2: constrained glycyl amides derived from the RGD tripeptide.EBI Merck Research Laboratories
9873697 15 Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonist with efficacy in a restenosis model.EBI SmithKline Beecham Pharmaceuticals
23140358 28 Synthesis and biological evaluation (in vitro and in vivo) of cyclic arginine-glycine-aspartate (RGD) peptidomimetic-paclitaxel conjugates targeting integrinaVß3.EBI Universit£ degli Studi di Milano
22959246 24 Camptothecins in tumor homing via an RGD sequence mimetic.EBI sigma-tau Industrie Farmaceutiche Riunite SpA
22871580 6 Near-infrared fluorescent divalent RGD ligand for integrinavß3-targeted optical imaging.EBI Washington University School of Medicine
22621422 2 ¹²5I-radiolabeled morpholine-containing arginine-glycine-aspartate (RGD) ligand ofavß3 integrin as a molecular imaging probe for angiogenesis.EBI University of Florence
22575869 61 Structure-activity relationship of a series of non peptidic RGD integrin antagonists targetinga5ß1: part 1.EBI AstraZeneca
22572578 124 Structure-activity relationship of a series of non peptidic RGD integrin antagonists targetinga5ß1: part 2.EBI AstraZeneca
20055426 30 Antiangiogenic effect of dual/selective alpha(5)beta(1)/alpha(v)beta(3) integrin antagonists designed on partially modified retro-inverso cyclotetrapeptide mimetics.EBI Universita degli Studi di Bologna
19860432 42 alphavbeta3 Integrin-targeting Arg-Gly-Asp (RGD) peptidomimetics containing oligoethylene glycol (OEG) spacers.EBI Universite Catholique de Louvain
18343671 8 Synthesis, SAR and in vitro evaluation of new cyclic Arg-Gly-Asp pseudopentapeptides containing a s-cis peptide bond as integrin alphavbeta3 and alphavbeta5 ligands.EBI Department of Organic Chemistry Ugo Schiff University of Firenze via della Lastruccia 13
18303826 48 Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues.EBI Universit£ di Parma
18068982 20 Design and synthesis of novel potent and selective integrin alphanubeta3 antagonists--novel synthetic routes to isoquinolinone, benzoxazinone, and quinazolinone acetates.EBI BASF AG
17184884 16 Identification of novel short chain 4-substituted indoles as potent alphavbeta3 antagonist using structure-based drug design.EBI Johnson& Johnson Pharmaceutical Research and Development
16302808 28 Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders.EBI Universit£ di Parma
15357991 20 Design, synthesis, and biochemical evaluation of novel alpha V beta 3 integrin ligands.EBI 3-Dimensional Pharmaceuticals, Inc
12139455 78 Selective alpha4beta7 integrin antagonists and their potential as antiinflammatory agents.EBI Genentech Inc.
9191954 9 Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists.EBI Merck Research Laboratories
10673106 28 RGD mimetics containing a central hydantoin scaffold: alpkha(v)beta3 vs alpha(IIb)beta3 selectivity requirements.EBI Hoechst Marion Roussel Deutschland GmhH
22365562 154 Fluorinated dual antithrombotic compounds based on 1,4-benzoxazine scaffold.EBI University of Ljubljana
21344906 54 Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry.EBI The University of Tokyo
20951038 3 Small molecule inhibitors of hantavirus infection.EBI University of New Mexico School of Medicine
20809642 28 Click-chemistry-derived triazole ligands of arginine-glycine-aspartate (RGD) integrins with a broad capacity to inhibit adhesion of melanoma cells and both in vitro and in vivo angiogenesis.EBI University of Florence
20218623 68 Emerging targets in osteoporosis disease modification.EBI Amgen, Inc.
19942441 47 Novel tumor-targeted RGD peptide-camptothecin conjugates: synthesis and biological evaluation.EBI Istituto di Ricerche Chimiche e Biochimiche G.Ronzoni
19574045 44 Novel inhibitors of the alphavbeta3 integrin--lead identification strategy.EBI AstraZeneca
19195898 8 Morpholine-based RGD-cyclopentapeptides as alphavbeta3/alphavbeta5 integrin ligands: role of configuration towards receptor binding affinity.EBI Università degli Studi di Firenze
19113865 6 Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using 18F-labeled PEGylated RGD-bombesin heterodimer 18F-FB-PEG3-Glu-RGD-BBN.EBI Stanford University School of Medicine
19081719 20 Synthesis and initial evaluation of novel, non-peptidic antagonists of the alpha(v)-integrins alpha(v)beta(3) and alpha(v)beta(5).EBI Pharmacopeia, Inc.
17244604 7 Structure-function analysis of Arg-Gly-Asp helix motifs in alpha v beta 6 integrin ligands.EBI Cancer Research UK Clinical Centre
17973471 24 Multiple N-methylation by a designed approach enhances receptor selectivity.EBI Technische Universität München
17910915 19 Biphenyls as potent vitronectin receptor antagonists. Part 3: Squaric acid amides.EBI Bayer Healthcare AG
17869121 32 Synthesis and biological evaluation of non-peptide alpha(v)beta(3)/alpha(5)beta(1) integrin dual antagonists containing 5,6-dihydropyridin-2-one scaffolds.EBI Università di Bologna
17616113 63 Design and synthesis of a new class of selective integrin alpha5beta1 antagonists.EBI Jerini AG
17399986 114 R-isomers of Arg-Gly-Asp (RGD) mimics as potent alphavbeta3 inhibitors.EBI Pfizer Global Research and Development
17387018 74 Discovery of +(2-{4-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl}-cyclopropyl)acetic acid as potent and selective alphavbeta3 inhibitor: design, synthesis, and optimization.EBI Pfizer Global Research and Development
16621534 87 Synthesis of pyrazoles and isoxazoles as potent alpha(v)beta3 receptor antagonists.EBI Pfizer Inc.
16509596 29 Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study of their conformational and biological behavior.EBI Istituto di Ricerche Chimiche e Biochimiche G. Ronzoni
16303301 44 Synthesis of 2,5-thiazole butanoic acids as potent and selective alpha(v)beta3 integrin receptor antagonists with improved oral pharmacokinetic properties.EBI Pfizer Global Research and Development
16298127 80 Convergent, parallel synthesis of a series of beta-substituted 1,2,4-oxadiazole butanoic acids as potent and selective alpha(v)beta3 receptor antagonists.EBI Pfizer Inc.
15974570 30 Ligand binding analysis for human alpha5beta1 integrin: strategies for designing new alpha5beta1 integrin antagonists.EBI Università di Napoli Federico II
15745815 7 Nonpeptide alpha(v)beta3 antagonists: identification of potent, chain-shortened 7-oxo RGD mimetics.EBI Merck Research Laboratories
15715463 16 Design, synthesis, and biological evaluation of novel potent and selective alphavbeta3/alphavbeta5 integrin dual inhibitors with improved bioavailability. Selection of the molecular core.EBI Johnson and Johnson Pharmaceutical Research & Development
15501072 58 1,2,3,4-Tetrahydroquinoline-containing alphaVbeta3 integrin antagonists with enhanced oral bioavailability.EBI Johnson & Johnson Pharmaceutical Research & Development
15380233 46 Piperidine-containing beta-arylpropionic acids as potent antagonists of alphavbeta3/alphavbeta5 integrins.EBI Johnson & Johnson Pharmaceutical Research and Development
15125957 23 N-Aryl-gamma-lactams as integrin alphavbeta3 antagonists.EBI Amgen Inc.
15109653 30 Discovery of a potent and selective alpha v beta 3 integrin antagonist with strong inhibitory activity against neointima formation in rat balloon injury model.EBI Dainippon Pharmaceutical Co., Ltd
15056002 112 Discovery of novel 2,8-diazaspiro[4.5]decanes as orally active glycoprotein IIb-IIIa antagonists.EBI Millennium Pharmaceuticals Inc.
15006384 179 Synthesis of cinnamic acids and related isosteres as potent and selective alpha v beta 3 receptor antagonists.EBI Pfizer Inc.
14741263 67 Solid-phase synthesis of a small library of 3-phenylthio-3-nicotinyl propionic acid derivatives acting as antagonists of the integrin alphaVbeta3.EBI Nerviano
14698164 39 Synthesis and biological evaluation of nonpeptide integrin antagonists containing spirocyclic scaffolds.EBI Pharmaceutical Research Institute
14640540 18 Molecular model of the alpha(IIb)beta(3) integrin.EBI Merck Research Laboratories
14561098 8 Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis.EBI Merck Research Laboratories
12729670 49 Non-peptide alphavbeta3 antagonists. Part 6: design and synthesis of alphavbeta3 antagonists containing a pyridone or pyrazinone central scaffold.EBI Merck Research Laboratories
12668017 17 Phenylbutyrates as potent, orally bioavailable vitronectin receptor (integrin alphavbeta3) antagonists.EBI GlaxoSmithKline Pharmaceuticals
12565960 33 Thiophene-based vitronectin receptor antagonists.EBI Shire BioChem Inc.
12565923 6 Solid-phase synthesis of cyclic RGD-furanoid sugar amino acid peptides as integrin inhibitors.EBI Leiden University
12482416 52 Highly potent and selective alphaVbeta3-receptor antagonists: solid-phase synthesis and SAR of 1-substituted 4-amino-1H-pyrimidin-2-ones.EBI BASF AG
12477347 16 Binding model for nonpeptide antagonists of alpha(v)beta(3) integrin.EBI Merck Research Laboratories
12392735 30 Substituted benzocyloheptenes as potent and selective alpha(v) integrin antagonists.EBI Institut de Recherches Servier
11855984 102 Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins.EBI Merck KGaA
11814816 30 Synthesis and SAR of N-substituted dibenzazepinone derivatives as novel potent and selective alpha(V)beta(3) antagonists.EBI Knoll GmbH
11714601 9 Discovery and evaluation of piperidinyl carboxylic acid derivatives as potent alpha(4)beta(1) integrin antagonists.EBI Bayer AG
11454469 95 alpha(v)beta(3) Antagonists based on a central thiophene scaffold.EBI Aventis Pharma Deutschland GmbH
11392539 34 Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 1: design of potent and specific 3,9-diazaspiro[5.5]undecanes.EBI COR Therapeutics, Inc
11384239 82 Solid-phase synthesis of a nonpeptide RGD mimetic library: new selective alphavbeta3 integrin antagonists.EBI Technische Universität München
11327582 23 2-Acylimino-3H-thiazoline derivatives: a novel template for platelet GPIIb/IIIa receptor antagonists.EBI Taisho Pharmaceutical Co. Ltd.
10853677 34 Discovery and evaluation of potent, tyrosine-based alpha4beta1 integrin antagonists.EBI Celltech Chiroscience
10633037 88 Disubstituted indazoles as potent antagonists of the integrin alpha(v)beta(3).EBI DuPont Pharmaceuticals Company
10633036 79 Isoxazolines as potent antagonists of the integrin alpha(v)beta(3).EBI DuPont Pharmaceuticals Company
10633035 20 Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic.EBI SmithKline Beecham Pharmaceuticals
10447947 14 N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists.EBI Technische Universität München
10406646 15 Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model.EBI SmithKline Beecham Pharmaceuticals
10406645 36 Orally bioavailable nonpeptide vitronectin receptor antagonists containing 2-aminopyridine arginine mimetics.EBI SmithKline Beecham Pharmaceuticals
10230615 60 Rapid synthesis of RGD mimetics with isoxazoline scaffolds on solid phase: identification of alphavbeta3 antagonists lead compounds.EBI Du Pont Pharmaceuticals Company
10197962 13 Orally active isoxazoline glycoprotein IIb/IIIa antagonists with extended duration of action.EBI The DuPont Merck Pharmaceutical Company
9873696 80 Benzimidazole derivatives as arginine mimetics in 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonists.EBI SmithKline Beecham Pharmaceuticals
9435900 89 Fibrinogen receptor (GPIIb-IIIa) antagonists derived from 5,6-bicyclic templates. Amidinoindoles, amidinoindazoles, and amidinobenzofurans containing the N-alpha-sulfonamide carboxylic acid function as potent platelet aggregation inhibitors.EBI COR Therapeutics, Inc.
9288166 74 Use of conformationally restricted benzamidines as arginine surrogates in the design of platelet GPIIb-IIIa receptor antagonists.EBI Lilly Research Laboratories
9240343 28 Discovery of potent nonpeptide vitronectin receptor (alpha v beta 3) antagonists.EBI SmithKline Beecham Pharmaceuticals
8057299 66 Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp.EBI Merck Research Laboratories
7507165 139 Design and synthesis of novel cyclic RGD-containing peptides as highly potent and selective integrin alpha IIb beta 3 antagonists.EBI Telios Pharmaceuticals, Inc.
1469694 22 Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors.EBI Merck Research Laboratories